Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase by Mousseau, G. et al.
Dimerization-driven interaction of hepatitis C virus




1 D. N. Frick





Received 4 May 2010
Accepted 23 September 2010
1Department of Infectology, The Scripps Research Institute (TSRI), Scripps-Florida, 130 Scripps
Way, #3C1, Jupiter, FL 33458, USA
2Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, 3210 N. Cramer
Street, Milwaukee, WI 53211, USA
Hepatitis C virus (HCV) infects over 130 million people causing a worldwide epidemic of liver
cirrhosis and hepatocellular-carcinoma. Because current HCV treatments are only partially
effective, molecular mechanisms involved in HCV propagation are actively being pursued as
possible drug targets. Here, we report on a new macromolecular interaction between the HCV
capsid core protein and the helicase portion of HCV non-structural protein 3 (NS3h), confirmed
by four different biochemical methods. The protease portion of NS3 is not required. Interaction
between the two proteins could be disrupted by two types of specific inhibitors of core
dimerization, the small molecule SL201 and core106, a C-terminally truncated core protein.
Cross-linking experiments suggest that the physical interaction with NS3h is probably driven by
core oligomerization. Moreover, SL201 blocks the production of infectious virus, but not the
production of a subgenomic HCV replicon by hepatoma cells. Time-of-addition experiments
confirm that SL201 has no effect on entry of the virus. These data underline the essential role of
core as a key organizer of HCV particle assembly, confirm the importance of oligomerization,
reveal the interaction with viral helicase and support a new molecular understanding of the
formation of the viral particle at the level of the lipid droplets, before its migration to the site of
release and budding.
INTRODUCTION
Hepatitis C virus (HCV) infects nearly 2.2% of the world
population and is a common cause of chronic liver disease
(Alter, 2007; Lavanchy, 2009). No vaccine is available,
and the only current treatment (combination therapy of
pegylated interferon with ribavirin) has limited efficacy and
serious side effects (Sakamoto & Watanabe, 2009; Tan
et al., 2002). HCV, an enveloped positive-sense ssRNA virus
(Choo et al., 1989), belongs to the genus Hepacivirus of the
family Flaviviridae. The 9.6 kb HCV genome encodes a
single 3000-residue precursor polyprotein cleaved by host-
cellular and viral enzymes into three structural proteins
(core, the envelope glycoproteins E1 and E2) and seven
non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B,
NS5A and NS5B) of diverse functions (Moradpour et al.,
2007). Core, the capsid protein, is essential for infectious
particle assembly and release (Miyanari et al., 2007; Penin
et al., 2004; Shavinskaya et al., 2007; Strosberg et al., 2010).
This protein of 191 residues consists of three distinct
domains: (i) D1, an N-terminal hydrophilic domain of
117 aa; (ii) D2, a more hydrophobic domain of about
60 aa; and (iii) the C-terminal D3 which contains approxi-
mately the last approximately 14 mostly hydrophobic
residues cleaved off during core maturation and which
serve as the signal peptide for the downstream protein E1
(Boulant et al., 2006). D1 is mostly responsible for self-
association, for binding RNA and for interaction with
several host cellular proteins (Angus et al., 2010; Chen et al.,
2008; Yan et al., 2007), whereas D2 is responsible for coating
of lipid droplets (LDs) and for the folding of the N-terminal
part (Appel et al., 2008; Boulant et al., 2005; Masaki et al.,
2008). Core dimers and higher-order complexes associate
with the viral RNA to form the nucleocapsid and associate
with E1 and E2 to form the infectious particles (Boulant
et al., 2005; Klein et al., 2004; Kunkel et al., 2001;
McLauchlan, 2000; McLauchlan et al., 2002). Recent
studies suggest that several steps of virus assembly take
place near the LDs and their associated membranes
(McLauchlan, 2009a; McLauchlan et al., 2009b Miyanari
et al., 2007; Rouille et al., 2006; Strosberg et al., 2010). The
interaction of NS5A with core and its recruitment to the
LDs (McLauchlan et al., 2002; Shi et al., 2002) appear to be
essential for virus assembly (Miyanari et al., 2007) and a
prerequisite for HCV particle production (Masaki et al.,
2008). In addition to the central role of core and that of
NS5A, several recent studies suggest that other NS proteins,
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important in viral assembly (Jones et al., 2007, 2009; Ma et
al., 2008; Murray et al., 2007, 2008; Steinmann et al., 2007;
Yi et al., 2007, 2009).
NS3 displays a serine protease activity at the N terminus
(aa 1–166), and helicase and nucleoside triphosphatase
activities in the remainder of the 631 residues of the
protein (Fig. 1a) (Gallinari et al., 1998). The NS3 protease
activity becomes fully active by association with NS4A. The
helicase portion of NS3 (NS3h) folds and functions
independently of the protease domain. Recent studies with
the HCV strain 2a J6/JFH-1 in infected cells suggest the
involvement of NS3h at an early step of viral assembly,
independently of its essential roles in polyprotein proces-
sing and in viral replication (Ma et al., 2008). However, the
physical interaction between HCV core and HCV helicase
was not demonstrated and a precise role for NS3 in virus
assembly and release remains unclear.
Several independent methods were used here to show that
HCV core protein indeed interacts directly with NS3h.
Moreover, inhibitors previously found to disrupt core
oligomerization and production of infectious particles
(Kota et al., 2009, 2010; Wei et al., 2009) abolish the core–
NS3 interaction in vitro, suggesting that dimerization of
core protein is important for the binding of helicase.
Collectively, these data underline the essential role of core
as a key organizer of HCV particle assembly.
RESULTS
Purification of core106, core169 and NS3h
The first N-terminal 106 residues of HCV core (core106)
were chosen as the minimum domain necessary to
homodimerize (Kota et al., 2009; Matsumoto et al., 1996;
Nolandt et al., 1997) and to mimic the hydrophilic domain
D1. The first 169 residues (core169) were selected to
represent mature core composed of domains D1+D2
(Boulant et al., 2005; Kota et al., 2009). Both core106 and
core169 homo/heterodimerize in a similar fashion, at
comparable concentrations. Proteins were expressed as such
oras fusionproteins with glutathione S-transferase(GST) or
Flag at their N terminus (Kota et al., 2009) and tagged with
eight His residues at their C terminus (Fig. 1a, upper panel).
GST-tagged HCV NS3 protein lacking the NS3 residues
1–166 (i.e. the protease domain) (here named NS3h or GST-
NS3h), unwinds both DNA and RNA duplexes at rates
comparable to those seen with the full-length NS3–NS4A
complex (Frick et al., 2004). The protein was produced as an
N-terminally GST-fused and a C-terminally 8-His-tagged
protein (Fig. 1a, lower panel). The proteins were purified to
apparent homogeneity from Escherichia coli extracts, by
using immobilized metal ion affinity chromatography and
followed, for GST-NS3h, by glutathione-bead purification.
The identity and homogeneity of the proteins were verified
by SDS-PAGE followed by Coomassie blue staining (Fig. 1b,
lanes 1–3) and immunoblotting (Fig. 1b, lanes 4–6),
revealing expected bands for core106, core169 (both contain
a C-terminal 8-His) and GST-NS3h at 15, 20 and 80 kDa,
respectively. (Of the 80 kDa for GST-NS3h, 50 kDa
correspond to the helicase domain and 30 kDa are
contributed by the GST protein and His-tag.)
Core interacts directly with NS3h
Recent studies suggest the involvement of NS3h at an early
step of viral assembly (Ma et al., 2008) and describe
colocalization of NS3 with core in LDs (Miyanari et al.,
2007). However, the physical interaction between core and
NS3 proteins was not demonstrated. An indirect sandwich
ELISA was used here for the initial characterization of the
interaction between affinity-purified HCV core and NS3h
proteins (Fig. 2a). When GST-NS3h was included in wells
coated with either core106 or core169, a strong signal was
observed revealing the interaction with the capsid protein.
An irrelevant GST-fusion protein (GST-IRP), used as a
negative control, gave a signal similar to the background in
the assay, confirming that the interaction between NS3h
and either core106 or core169 was specific (Fig. 2a).
To measure the strength of the core–NS3h interaction, we
adapted a previously developed Amplified Luminescent
Proximity Homogeneous Assay (AlphaScreen) to follow
core dimerization using GST-fused and Flag-fused core
Fig. 1. (a) HCV core protein and NS3 protein
constructs. (b) Analysis of purified HCV core
and NS3h protein. Lanes 1 and 4: core106
(15 kDa); lanes 2 and 5: core169 (20 kDa);
and lanes 3 and 6: GST-NS3h (80 kDa) were
resolved by SDS-PAGE and stained with
Coomassie blue (lanes M and 1–3) or
detected by immunoblotting using mouse
monoclonal anti-core or anti-helicase anti-
bodies (lanes 4–6). The immunoblot revealed
also minor degradation products of core106
(13 kDa), core169 (14 and 17 kDa) and GST-
NS3h (60 kDa).
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2009). This assay, displaying a signal-to-background ratio
greater than 50-fold, confirmed both the Flag-core106–
GST-NS3h and the Flag-core169–GST-NS3h interactions
(Fig. 2b). Several groups have previously reported that the
cellular DEAD-box protein DDX3, a human helicase
homologous to HCV NS3h, interacts with viral core
(Angus et al., 2010; Mamiya & Worman, 1999; Owsianka
& Patel, 1999; You et al., 1999): the first 40 aa residues of
the N-terminal part of HCV core are important for this
interaction. We evaluated the effects of five peptides
spanning the 44 first residues of the N-terminal part of
core (Fig. 2c) by AlphaScreen. The two most potent mostly
hydrophilic peptides were able to inhibit core–NS3h
interaction by about 80%, indicating that residues localized
between 1 and 24 are important for the interaction but other
residues of core are also required.
Full-length NS3 from HCV-infected cells interacts
with the N-terminal domain of core
First, the expression of core, NS3 and NS5A in HCV-
infected Huh-7.5 cells was verified by immunoblotting
revealing the expected molecular mass of the full size
proteins: 20, 70 and 65 kDa, respectively (Fig. 2d). A GST
pull-down assay was then used to verify that NS3 and
Fig. 2. Direct interaction of core with NS3h. (a) Sandwich ELISA revealing the interaction between either core106 or core169
coated on the plate with GST-NS3h. The background controls in the assay contained buffer only, core106 alone and core169
alone (mean absorption of 0.06 mAU) and were used to normalize the signal. An irrelevant GST-fusion protein (GST-IRP) was
used as a negative control. The data shown were representative of three independent experiments with triplicate data points in
each experiment. (b) AlphaScreen showing interaction of either Flag-core106 (FC106) or Flag-core169 (FC169) with GST-
NS3h. The GST-core106 (GC106)–FC106 interaction was included as a positive control. The data shown were one out of
three representative experiments with duplicate assay points. (c) Core-derived peptides spanning the first 1–44 residues on
core–NS3h interaction tested by AlphaScreen. A Student’s t-test confirms that the difference between the uninhibited control
compared with the inhibition by the peptides (1–18 and 7–24) was statistically significant. The data shown are representative of
three independent experiments with duplicate data points in each experiment. (d) Cell lysates infected with HCV 2a J6/JFH-1
virus were analysed by immunoblotting and revealed the presence of HCV core, NS3 and NS5A proteins. (e) GST pull-down of
NS3 by GST-core106 from the lysate. NS5A was also pulled down as a control for the assay. The resulting precipitates were
examined by immunoblotting using anti-NS3 antibody (top panel) or NS5A (bottom panel). One-tenth of the cell lysate used in
the GST pull-down assay was immunoblotted for NS3 and NS5A as the input control. (f) GST pull-down of NS3 by GST-
core106 in the presence of RNase.
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interactwithcore (Fig.2e). Afterincubation of GST-core106
with a lysate of HCV-infected Huh-7.5 cells, the protein
complexes were pulled down by glutathione-Sepharose
beads and analysed by immunoblotting using mouse anti-
NS3 and anti-NS5A antibodies. As a negative control, the
cell lysate was incubated with beads alone to exclude non-
specific interactions of NS3 with the glutathione-Sepharose
beads. Moreover, GST-IRP was analysed in parallel to
exclude the eventual participation of the GST moiety in the
interaction. The presence of protein bands of apparent
molecular mass of 70 and 65 kDa, respectively, seen only
with beads coated with GST-core106, confirmed specific
pull-down of the full-length NS3 and NS5A produced in
cells (Fig. 2e). A 2 h RNase treatmentof GST-core106and of
the cell lysate did not decrease the amount of pulled-down
proteins, suggesting that interaction between core and NS3
is not mediated by RNA (Fig. 2f).
Core oligomerization is required for binding of
NS3h
Core is known to oligomerize to form the viral particle
(Klein et al., 2004; Kunkel et al., 2001). We investigated the
size of the complex formed between core and NS3h by
performing cross-linking experiments using dimethyl
suberimidate (DMS), which reacts with amino groups,
and which we previously used to characterize core
oligomerization (Kota et al., 2009). While no evidence
was found for cross-linking of a core106 monomer to NS3h
monomer (expected molecular mass 95 kDa), trimer
formation was readily apparent between core106 dimer
(30 kDa) and GST-NS3h (80 kDa): the identity of the band
of the expected total size of 110 kDa (Fig. 3a) was
confirmed by immunoblotting with both anti-core and
anti-GST antibodies (Fig. 3b). With core169, GST-NS3h
formed not only trimers (120 kDa) but also tetramers
(140 kDa) (Fig. 3c, d). The immunoblots confirm the
presence of both core169 and NS3h in these two bands.
Regarding apparent molecular masses, the trimers and
tetramers may correspond to the interaction of GST-NS3h
(80 kDa) with two (2620 kDa) or three molecules of
core169 (3620 kDa), respectively. Higher molecular-mass
oligomers, associated with NS3h are also visible for core106
(Fig. 3a, b) and core169 (Fig. 3c, d).
Interestingly, in the AlphaScreen experiments, the inter-
action between GST-NS3h and core yielded a signal
superior to that seen for the core–core interaction alone,
reflecting a better transfer of energy between GST-NS3h
and the two molecules of dimerized Flag-core (Fig. 2b).
Disruption of HCV core–NS3h interaction by
inhibitors of core dimerization confirms role of
oligomerization
To verify the role of dimerization of core in the binding of
NS3h, we evaluated the effects of an inhibitor (SL201) and
of a competitor (core106) by AlphaScreen (Kota et al.,
2010; Wei et al., 2009). Buffer only and individual protein
partners in the presence of donor/acceptor beads alone
provided the background value for the assay (Fig. 4a).
Addition of 1% DMSO without SL201 did not reveal any
effect of the solvent on the interaction. As positive control,
we used the Flag-core106–GST-core106 interaction (Fig.
4a). The AlphaScreen showed the Flag-core106– and Flag-
core169–GST-NS3h interactions were inhibited by core106
(10 mM) and SL201 (15 mM) (Fig. 4b). Core106 inhibited
the Flag-core106–GST-NS3h interaction with an IC50 of
0.344 mM, i.e. four times higher than the IC50 of 0.089 mM
for the core106 homodimer (Fig. 4c and Table 1). The
higher IC50 could be explained by the need for two
molecules of core106 to abrogate completely the inter-
action between Flag-core106 dimer and GST-NS3. The
inhibition by one molecule of core106 only weakened the
signal partially. Similarly, the IC50 for the Flag-core169–
GST-NS3h was 0.873 mM (Fig. 4e and Table 1). SL201, a
513 Da inhibitor of core106 dimerization, was discovered
when screening with a time-resolved fluorescence res-
onance energy transfer (TR-FRET)-based screen assay, the
Center for Chemical Methodology and Library Develop-
ment at Boston University library of 2240 compounds
(Kota et al., 2010; Wei et al., 2009). When evaluated on the
Flag-core106– or Flag-core169–GST-NS3h pairs of pro-
teins, SL201 strongly inhibited (~90%) these interactions
(Fig. 4b). In a dose–response format, SL201 displayed
strikingly consistent IC50 values ranging from 9.3 mM for
the homologous core106 self-association to 9.0 mM and
10.5 mM for Flag-core106–GST-NS3h and Flag-core169–
GST-NS3h interactions, respectively (Fig. 4d, f and
Table 1). These results suggest that it is most likely that
SL201 acts on the same single interaction site on core,
regardless of the protein interaction partner, in contrast to
what is observed when the much larger core106 molecule is
used as the disruptor of the interaction.
Treatment by SL201 abolishes infectious virus
production
Recently developed cell-culture-based systems for produc-
tion of infectious HCV from genotype 2a JFH-1 have
facilitated the study of the virus life cycle (Lindenbach
et al., 2005; Wakita et al., 2005; Zhong et al., 2005). SL201
was previously shown to substantially decrease HCV
production by HCV-infected Huh-7.5 cells, as revealed
by quantitative RT-PCR (Kota et al., 2010; Wei et al.,
2009). The compound was added here at various dilutions
with infectious supernatant from electroporation of 2a J6/
JFH-1 RNA into naı ¨ve cells and incubated for 3 days (early
stage – T1). This stage corresponds to the entry and
replication of the virus. T1 culture supernatant was used to
infect naı ¨ve cells to study infectivity (late stage – T2)
(Fig. 5a). The compound was shown to be active with an
effective concentration at 50% (EC50) of 8.8 mM for T1
and 8.1 mM for T2 (Fig. 5b). The compound SL201 had no
effect on production of a subgenomic HCV replicon which
G. Mousseau and others
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compound does not affect replication and supports the
hypothesis that it blocks HCV particle assembly by acting
on core or core’s interactions with other HCV proteins,
including NS3 (Fig. 5c).
DISCUSSION
Until recently, the only known role for HCV NS3 in the
viral life cycle was thought to be linked to its protease
activity in HCV polyprotein processing and its helicase
activity in viral replication. There is, however, growing
evidence that NS3 may participate in the assembly/
production of infectious viral particles (Ma et al., 2008;
Murray et al., 2008; Patkar & Kuhn, 2008), as do other NS
proteins such as NS5A (Appel et al., 2008; Miyanari et al.,
2007; Tellinghuisen et al., 2008) and NS2 (Jirasko et al.,
2008; Jones et al., 2007; Murray et al., 2007; Yi et al., 2007,
2009). With regard to NS3h, two successive spontaneous
mutations were identified that restored the production of
infectious virus by a strain that was otherwise quite
unproductive (Ma et al., 2008). Core and NS3h were also
found to be colocalized on LDs of cells transfected with
HCV RNA (Ma et al., 2008; Miyanari et al., 2007).
In the present work, we demonstrate for the first time that
NS3h directly interacts with core as shown by several
biochemical methods. After showing the physical inter-
action between recombinant affinity-purified core and
NS3h proteins by ELISA and AlphaScreen, we confirmed
the interaction of GST-core106 with the full-length NS3
protein produced in HCV-infected hepatoma cells using a
GST pull-down assay. We verified that prior treatment
with RNase did not reduce the interaction, thus discarding
an indirect effect due to the presence of RNA. Taken
together, these experiments showed that NS3h binds to
HCV core and that the N-terminal fragment core106 and
the helicase domain of NS3 (167–631) are sufficient for the
interaction. Using an AlphaScreen, the ability of core106 to
block association of GST-NS3h with Flag-core106 con-
firmed the involvement of N-terminal residues in the
interaction. By screening the ability of peptides spanning
the N-terminal part of core known to interact with DDX3,
a human homologue of HCV NS3h (You et al., 1999), two
peptides, 1–18 and 7–24, were found to block binding by
Fig. 3. Cross-linking of HCV core protein oligomers with HCV NS3h. (a, c) SDS-PAGE stained with Coomassie blue of
core106 (C106) and core169 (C169), respectively, with or without GST-NS3h cross-linked in the presence of DMS. (b, d)
Immunoblotting with an anti-core antibody (left) or anti-GST antibody (right).
Interaction of HCV core protein with NS3 helicase
http://vir.sgmjournals.org 10580%, indicating the importance of one or several
residue(s) of those N-terminal peptides in the interaction.
Moreover, the C-terminal region of core may contain
additional residues important for the binding since
interaction between NS3h and core169 displays a higher
signal than that between core106 and NS3h as shown by
AlphaScreen.
We previously developed an ELISA and an AlphaScreen
using core106, the region essential for self-association, and
identified SL201, a small molecule that inhibits HCV core
dimerization (Kota et al., 2010; Wei et al., 2009). Core106
and SL201 potently inhibit the binding with the helicase.
Using a molecular beacon-based helicase assay (Belon &
Frick, 2008), no effect of SL201 was observed on DNA
Fig. 4. Inhibition of core–NS3h interaction by core dimerization inhibitors. (a) Positive and negative controls of the AlphaScreen
experiments performed in Fig. 4(b). Buffer, GST-core106 (GC106), Flag-core106 (FC106), GST-NS3h, Flag-core169
(FC169) and SL201 with beads only were included in the assay as negative controls. All these controls displayed a signal close
to background. GC106 and FC106 at 150 nM each were included in the assay as a positive control for interaction in the
presence or absence of DMSO. (b) AlphaScreen showing inhibitions of FC106– and FC169–GST-NS3h interactions by
core106 (10 mM) and SL201 (15 mM). The data shown were representative of three independent experiments with duplicate
data points in each experiment. Student’s t-test confirmed that the difference between the uninhibited control compared with
the inhibition by core106 or SL201 was statistically significant. (c, d, e and f) Representative graphs showing dose–response
analysis of (c) core106 or (d) SL201 as inhibitors of FC106–GST-NS3h; and (e) core106 or (f) SL201 as inhibitors of FC169–
GST-NS3h. Dose range for core106 was from 125 pM to 2.5 mM and for SL201 was from 0.05 mM to 100 mM. Data points are
presented in terms of percentage inhibition, which was calculated using the uninhibited control as 0% reference. The data
shown are representative of four independent experiments with duplicate data points in each experiment.
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strong inhibition by core106 and SL201 suggests that NS3h
recognizes and interacts preferentially with dimers or
oligomers of core. This observation is strengthened by
the cross-linking experiments, which show that NS3h
interacts with core106 dimers and core169 dimers and
trimers, but not monomers. The presence of cross-linked
tetramers containing core169 trimers and NS3h but not
core106 trimers suggests that NS3h better stabilizes
oligomeric forms of core169 than of core106.
The NS3 protein of yellow fever virus (YFV), the prototype
flavivirus, which like HCV is a member of the family
Flaviridae, also plays an essential role in virus assembly
as shown by trans-complementation of a mutation
(Trp349Ala) by expression of the wild-type NS3 protein
(Patkar & Kuhn, 2008). Since domains 1 and 2 of the HCV
helicase show a high degree of similarity with the
corresponding domains in YFV helicase, and the sequence
alignment reveals 21% similarity including the presence of
a conserved aromatic residue (Tyr350) in HCV at the
position corresponding to 349 in YFV (Wu et al., 2005),
they may also share mechanistic features in the process of
virus assembly and release. The interaction observed
between core and NS3h might be equally important for
HCV assembly. We propose the following sequence of
events: initially, HCV core is processed by signal peptide
peptidase, oligomerizes, and then progressively coats LDs
and recruits NS5A and NS3 to the LDs, a prerequisite for
particle assembly (Appel et al., 2008; Ma et al., 2008;
McLauchlan, 2009a; Miyanari et al., 2007; Strosberg et al.
2010; Tellinghuisen et al., 2008). SL201 potently blocks
HCV production by infected hepatoma cells (Kota et al.,
2010; Wei et al., 2009), but had no effect on multiplication
of human immunodefiency virus in CD4-transfected HeLa
cells (S. Valente, personal communication). The com-
pound did not modify HCV replicon propagation,
indicating lack of effect on viral replication. These results
suggest that the inhibitor disrupts viral particle assembly.
To differentiate between an effect on assembly and entry,
time-of-addition intracellular and extracellular infectivity
assays were performed. To analyse the results, we used both
real-time RT-PCR and HCV-limiting-dilution (TCID50)
assays. These data confirm that SL201 appears at least 10-
fold less effective when added before viral infection than
during or after infection (see Supplementary Figs S1 and S2
and Supplementary Table S1, available in JGV Online).
The colocalization and interaction of core with NS proteins
on LDs confirms core as a key organizer of virus assembly
and suggests that it acts by recruiting the replication
complex near the site of assembly to facilitate the
packaging and integration of the newly synthesized RNA.
Whether core actually modulates the HCV RNA unwind-
ing activity of the viral helicase, and thus actually affects
replication and translation, remains an open question.
In conclusion, the present studies establish that HCV
helicase physically interacts with the oligomerized HCV
core protein, and that this interaction involves the first 106
residues from core and residues 166–631 from NS3.
Binding is stronger when domain D2 of core, up to
residue 169, is present, and is inhibited by small molecule
SL201, a disruptor of core dimerization and of infectious
HCV production.
METHODS
Materials. Anti-GST (Sigma-Aldrich), anti-core (MA1-080)
(Thermo Scientific), anti-NS3 [H23] (Abcam), anti-NS5A [9E10] (gift
from Dr T. Tellinghuisen, Scripps-Florida, USA) were purchased.
HRP-conjugated secondary antibodies were obtained from Jackson
ImmunoResearch. Infectious HCV 2a strains J6/JFH-1 and JC1 were
produced using previously published protocols (Lindenbach et al.,
2005; Pietschmann et al., 2006; Wakita et al., 2005; Zhong et al.,
2005). Cells were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% heat-inactivated FBS
(Akron Biotech), 1X Pen-Strep-Gln and 16 non-essential amino
acids (Invitrogen) at 37 uC in a humidified atmosphere with 5% CO2.
Cloning, expression and purification of proteins. A vector
encoding GST-NS3h (from HCV HC-J6CH genotype 2a;
AF177036) was generated by excising the HCV helicase-encoding
region from p24Hel-2a (Lam et al., 2003) and inserting it into vector
pET41a. Recombinant protein was expressed in transformed E. coli
BL21(DE3) cells and purified by Hi-Trap nickel-nitrilotriacetic acid
(Ni-NTA) column and affinity-capture of GST-NS3h with gluta-
thione-Sepharose beads as described previously (Lam et al., 2003).
The cloning, expression and purification of the recombinant HCV
core106, Flag-core106 and GST-core106 were done as described
previously (Kota et al., 2009). Core106 was further purified for the
cross-linking assays by reverse-phase HPLC on a semi-preparative
column Agilent Zorbax Extend C18 using an isocratic (0–5 min, 22%)
followed by linear gradients (5–55 min, 32%; 55–60 min, 100%) of
buffer B (acetonitrile, 0.01% trifluoracetic acid) at 2 ml min
21 flow
rate and at room temperature. Core106 fractions were dialysed
overnight at 4 uC against 20 mM Tris (pH 8.0), 0.5 M NaCl and
stored at 280 uC.
The sequences of core covering the first 169 residues were amplified
by PCR from HCV H77 genotype 1a (NC-004102) plasmid pCV-
H77C and inserted into pET42b. For expression, this plasmid or
Table 1. IC50s of core106 and SL201 to block GST-NS3h
and core interactions
IC50s were calculated from Fig. 4 using Graphpad Prism software.
IC50s were calculated using an ‘n of 2’ with duplicate data points. ‘+’
Indicates that core106 or core169 is actually present as a dimer or
trimer in the complex formed with NS3. ‘*’ Indicates data previously













+ NS3h 0.22±0.15 9.00±1.00
Core169
+ NS3h 0.87±0.53 10.50±2.00
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http://vir.sgmjournals.org 107Fig. 5. Effect of SL201 on HCV 2a J6/JFH-1 virus and PSGR-JFH1 replicon. (a) Scheme of infection of naı ¨ve Huh-7.5 cells by
HCV. Infectious supernatants were obtained from cells electroporated with RNA from HCV (Kota et al., 2009). (b) Inhibition
assay of SL201 was performed on HCV 2a J6/JFH-1 virus by adding serially diluted SL201 and virus onto naı ¨ve Huh-7.5 cells
and then incubating for 3 days (T1). Culture supernatant from T1 was transferred onto naı ¨ve Huh-7.5 cells and the cells were
incubated for an additional 3 days (T2). RNA was purified from lysed cells from both T1 and T2 and analysed by real-time RT-
PCR. EC50 values for this new batch of SL201 were 8.8 mM and 8.1 mM, respectively. (c) Effect of SL201 on PSGR-JFH1
replicon cells. Inhibition assay of SL201 was performed on PSGR-JFH1 replicon cells by adding serially diluted SL201 onto
cells and incubating for 3 days. RNA was purified from cell lysates and analysed by real-time RT-PCR. RNA production from
cells in the presence of various concentrations of SL201 was compared with the cell-only control. Data points are presented in
terms of percentage inhibition, which was calculated using the uninhibited control as 0% reference. These are representations
of one experiment with triplicate data points.
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coli BL21(DE3) cells using standard expression procedure (Boulant
et al., 2005). Core169 (containing only an 8-His tag) or Flag-core169-
containing pellets were solubilized using lysis buffer containing 6 M
urea (Thermo Fisher Scientific) and the clarified lysate was applied to
Ni-NTA affinity columns pre-equilibrated with 20 mM Tris/HCl
buffer (pH 8.0), 0.5 M NaCl, 6 M urea and 0.1% dodecyl b-
maltoside (DM; Sigma-Aldrich). Recombinant proteins were eluted
with 50, 100 and 150 mM imidazole (Thermo Fisher Scientific) and
dialysed overnight at 4 uC against 20 mM Tris (pH 8.0), 0.1% DM
and stored at 280 uC. The homogeneity of the purified proteins was
determined by SDS-PAGE and confirmed by immunoblotting using
mouse monoclonal anti-core antibodies.
Indirect sandwich ELISA. The assay was performed similarly as
described previously (Kota et al., 2009). Core106 and core169
(500 pmol) were coated to high-binding 96-well plates and GST-
fusion proteins were tested at 1 pmol per well. Rabbit anti-GST
antibodies were used at a dilution of 1:1000 and anti-rabbit IgG-HRP
antibodies were added at a dilution of 1:10000. Colour develop-
ment was assessed by using the Ultra 3,39,5,59–tetramethybenzidine
(Thermo Fisher Scientific). The colour reaction was stopped by
adding 1 N H2SO4 and absorbance measured at 450 nm.
GST pull-down. Huh-7.5 cells were grown for 24 h before
electroporation with infectious HCV 2a strain J6/JFH-1. At day 4
post-electroporation, the supernatant was removed and cells were
lysed in 400 ml lysis buffer (PBS with 1% Triton X-100, 1 mM PMSF,
protease-inhibitor cocktail) and stored at 220 uC. The presence of
HCV proteins core, NS3 and NS5A in cell lysate was verified by
immunoblotting using anti-core, anti-NS3 and anti-NS5A antibodies.
For GST pull-down, GST-core106 or GST-IRP (kindly provided by
Dr N. Ayad, Scripps-Florida) immobilized on glutathione-Sepharose
4B beads (GE Healthcare Biosciences) was incubated with 80 ml of cell
lysate in incubation buffer [20 mM Tris (pH 8.0), 150 mM NaCl,
10% glycerol, 0.05% Triton X-100] for 4 h at room temperature
under end-over-end agitation. As control, GST-core106 and the cell
lysate were alternatively treated with 10 U of RNase (New England
Biolabs) at 37 uC for 2 h. The beads were washed three times and
centrifuged at 5000 g for 1 min using a SigmaPrep spin column and
boiled in the SDS loading buffer for 5 min, and the pulled-down
proteins were detected by immunoblotting.
Cross-linking analysis. For cross-linking experiments, core106 and
NS3h were dialysed against cross-linking buffer (200 mM phosphate
buffer, pH 8.0), and core169 in cross-linking buffer containing 0.01%
CHAPS, and stored at 280 uC. Cross-linking analysis was performed
by incubating 8 mM of core106 or core169 proteins with or without
2.5 mM of NS3h in cross-linking buffer followed by the addition of
200 molar equivalents of DMS for 1 h at room temperature. The
reaction was stopped by adding an equal volume of SDS loading
buffer and sample was boiled for 10 min. The products were resolved
by SDS-PAGE and analysed by Coomassie blue staining or by
immunoblotting using anti-core and anti-GST antibodies to detect
core and GST-NS3h, respectively.
AlphaScreen. This method was developed as described previously
(Kota et al., 2009). In brief, the GST-fusion proteins and Flag-fusion
proteins at a concentration of 208 and 250 nM, respectively, were
used. GST-core106 and Flag-core106 at 150 nM each were included as
a positive control. Alternatively, in order to evaluate the possible role
of RNA in the core–NS3h interaction, proteins were treated with
10 U of RNase A for 2 h at 37 uC. The untagged core106 domain
(10 mM) or compound SL201 (15 mM) (previously published as
compound #15) (Wei et al., 2009) were added to the proteins
as reference competitors. Core-derived peptides were evaluated as
potential inhibitors on core–NS3h interaction and/or core–core
interaction at 40 mM concentration. Anti-Flag acceptor beads and
glutathione donor beads were added to the proteins at a final
concentration of 20 mgm l
21. The data of the uninhibited control
compared with the inhibition by either core106 or SL201 were
analysed using unpaired Student’s t-test.
Inhibition of HCV 2a J6/JFH-1 in Huh-7.5 cells. The addition of
SL201 to infected cells was done as per previously published protocols
(Kotaetal., 2009) for an initial72 hperiod(T1)andan additional72 h
(T2). The compound was dosed from 200 mM, 100 mM, and then 1:3
serial dilutions down to 0.015 mM. For time-of-addition experiments,
naı ¨ve Huh-7.5 cells were treated with serial dilutions of compound
from 1 to 100 mM before (for 6 h), during and after (24 h) infection
with HCV2a JC1. Supernatants from cells were removedandtitrated at
10
-6 dilution for HCVcc-limiting-dilution assay to determine TCID50
values (Lindenbach et al., 2005). Infected cells were lysed by three
freeze–thaw cycles and titratedin mediumto 10
26 dilution for HCVcc-
limiting-dilution assay to obtain TCID50 values. Cells in a duplicate
plate were lysed for RNA analysis by real-time RT-PCR.
PSGR-JFH1 replicon cell assay. PSGR-JFH1 replicon cells
(Tellinghuisen et al., 2008) were maintained in G418 selection and
taken out of selection for assay. Cells were plated into 24-well plates
and incubated with 0.195–200 mM final concentration of SL201 for
3 days, along with a cells-only control. Cells were then lysed for RNA
purification with Qiagen RNeasy kit. Real-time RT-PCR was
performed on RNA samples, using Roche’s LightCycler RNA
amplification kit HybProbe, for analysis.
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